The spatially resolved analysis by QIF revealed that ~ 42.4% of 819 immunotherapy naive primary NSCLCs from multiple independent cohorts, and including early stage/resectable tumors, show cancer cell selective downregulation of TAP2 protein. The gene discussed is TAP2; the disease is cancer.